FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to oncology and can be applied for treatment of lung cancer. Essence of claimed method lies in the following: topotecan and aranose are introduced intraperitoneally in doses: for topotecan 0.5 mg/kg or 1 mg/kg, for aranose 100 mg/kg sequentially with interval 10-15 min twice or thrice.
EFFECT: application of method makes it possible to increase efficiency of lung cancer treatment due to inhibition of tumor growth, increase of life duration and reduction of toxicity under impact of topotecan and aranose combination.
2 tbl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD OF LUNG CANCER TREATMENT | 2008 |
|
RU2365370C1 |
LUNG CANCER THERAPY | 2008 |
|
RU2367436C1 |
PHOSPHOLIPID COMPOSITION OF DOXORUBICIN FOR TREATING PATIENTS WITH BREAST CANCER | 2019 |
|
RU2714137C1 |
TUMOUR THERAPY AGENT | 2019 |
|
RU2726801C1 |
METHOD OF COMBINED THERAPY FOR CONNECTIVE TISSUE SARCOMA M-1 IN RATS USING A CONJUGATE OF DIPROPOXYBACTERIOPURPURIN WITH DOXORUBICIN | 2023 |
|
RU2808909C1 |
METHOD FOR INHIBITION OF TUMOR GROWTH | 2003 |
|
RU2255742C2 |
METHOD FOR TREATMENT OF SW620 HUMAN COLON CANCER IN EXPERIMENT | 2017 |
|
RU2665168C1 |
AGENT BASED ON ENAMINOHYDRAZONOTHIAZOLE DERIVATIVE OF USNIC ACID, HAVING ABILITY TO ENHANCE CYTOTOXIC, ANTICANCER AND ANTIMETASTATIC ACTION OF TOPOTECAN | 2024 |
|
RU2833910C1 |
ORAL ANTITUMOUR DRUGS AND METHOD FOR ONCOLOGICAL DISEASES TREATMENT | 2016 |
|
RU2639479C1 |
WATER-SOLUBLE DOSAGE FORM OF MESO-TETRA(3-PYRIDYLE)BACTERIOCHLORIN FOR PHOTODYNAMIC THERAPY | 2017 |
|
RU2663900C1 |
Authors
Dates
2011-03-27—Published
2009-06-29—Filed